Heterogeneous burden of lung disease in smokers with borderline airflow obstruction

Pirozzi, Cheryl S; Gu, Tian; Quibrera, Pedro M; Carretta, Elizabeth E; Han, MeiLan K; Murray, Susan; Cooper, Christopher B; Tashkin, Donald P; Kleerup, Eric C; Barjaktarevic, Igor; Hoffman, Eric A; Martinez, Carlos H; Christenson, Stephanie A; Hansel, Nadia N; Graham Barr, R; Bleecker, Eugene R; Ortega, Victor E; Martinez, Fernando J; Kanner, Richard E; Paine, Robert

Name:

s12931-018-0911-z.pdf

Size:

847.5Kb

Format:

PDF

Description:

Final Published version

Download

Publisher

BMC

Citation

Pirozzi, C. S., Gu, T., Quibrera, P. M., Carretta, E. E., Han, M. K., Murray, S., ... & Hoffman, E. A. (2018). Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. Respiratory research, 19(1), 223.

Journal

RESPIRATORY RESEARCH

Rights

Collection Information

This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.

Abstract

The identification of smoking-related lung disease in current and former smokers with normal FEV1 is complex, leading to debate regarding using a ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) of less than 0.70 versus the predicted lower limit of normal (LLN) for diagnosis of airflow obstruction. We hypothesized that the discordant group of ever-smokers with FEV1/FVC between the LLN and 0.70 is heterogeneous, and aimed to characterize the burden of smoking-related lung disease in this group.

Note

Open Access Journal.

ISSN

1465-993X

PubMed ID

30454050

DOI

10.1186/s12931-018-0911-z

Version

Final published version

Sponsors

NIH/NHLBI [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C]; AstraZeneca; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; Forest Research Institute, Inc.; GSK; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Company; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi; [R01 HL122438]; [K24 HL138188]

Additional Links

https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0911-z

Collections

UA Faculty Publications

© The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

Except where otherwise noted, this item's license is described as © The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).